Pharmafile Logo

Convergence

- PMLiVE

Biogen Idec posts solid Q4 results and says more to come

MS drugs Tysabri and Avonex lift sales

- PMLiVE

Biogen Idec, Elan file Tysabri for first-line use

US and EU multiple sclerosis drug submissions follow companion diagnostic approval

- PMLiVE

Biogen Idec licenses antisense drugs from Isis in $630m deal

Gains neurological and neuromuscular disorder projects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links